From April 15 to 18, Ekaterinburg hosted the 6th international specialized exhibition and forum Healthcare of the Urals–2025. This year, 130 companies from 34 cities of Russia and the Republic of Belarus took part in the event, presenting over 1000 units of medical equipment and goods. The residents of the Ural Biomedical Cluster were traditionally among the participants, as well as its collective member – the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region.
On April 6, the First Children's Polyclinic in the Akademichesky District celebrated its 10th anniversary. During this time, the institution has become a flagship of high-quality and affordable medical care for children, serving 33,083 young patients. The polyclinic was created by the initiative of the Ural Biomedical Cluster and the Governor of the Sverdlovsk Region and became a successful example of public-private partnership.
A meeting of the Committee on Entrepreneurship in Healthcare and Medical Industry of the Ural Chamber of Commerce and Industry was held in Ekaterinburg on March 18, 2025, chaired by Alexander Petrov. Participants of the event, including representatives of the Association of Medical Specialists for Risk Modification, the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region, the Ural Biomedical Cluster and members of the Committee considered key challenges in maintaining the health of the able-bodied population, fighting against socially significant diseases and regulating prices for vital drugs.
The Russian pharmaceutical industry has gained significant stability in the recent years thanks to manufacturers such as Medsintez Plant. This is a modern full-cycle biotechnological enterprise that develops and manufactures pharmaceutical ingredients and drugs that meet international GMP and ISO standards.
The institute includes 5 laboratories and 4 groups. On the basis of the Institute of Organic Synthesis, there are branches of the Departments of Organic Chemistry of the Ural Federal University, joint laboratories with the Department of High- Molecular Compositions of the Ural Federal University and the Faculty of Chemistry of the Chelyabinsk State University, Research Equipment Sharing Center of the Ural Branch of the Russian Academy of Sciences “Spectroscopy and Organic Compound Analysis”, laboratory of the Ural Scientific and Educational Center “Advanced Materials”.
Development of the Institute is
based on the following
guidelines:
1. Combining the best traditions
of the Urals scientific school of
organic chemists with
innovative approaches to
development of fundamental
research aimed at creating new
methodologies for organic
synthesis, taking into account
the latest achievements of world science in such important
areas as C-H functionalization
of aromatic and heteroaromatic
substances, synthesis of
enantiomerically pure
biologically active compounds,
chemistry of fluorine-containing
compounds, chemistry of
organo(boron)element
compounds, asymmetric
catalysis, supramolecular and
coordination chemistry,
transformations of
heterocycles, electro- and
photosynthesis, chemistry of
monomers and polymers, gas-,
oil- and coal chemistry.
2. Reasonable balance of
fundamental and applied
research.
Development of fundamental
research in organic synthesis,
focused on creation of drugs
combating infectious diseases
of viral and bacterial etiology,
including those active against
viruses, bacteria and
mycobacteria with multidrug
resistance, as well as
anticancer, anti-inflammatory
and other chemotherapeutic
agents.
Medical and biological studies
of drugs as part of preclinical
and clinical studies thereof.
3. Development of fundamental
and applied research in the
field of organic materials
science, as the most important direction of the Strategy for
Scientific and Technological
Development of the Russian
Federation.
Strengthening cooperation with
universities and enterprises of
the real sector of economy.
Carrying out a full cycle of
research and development
applied work to create new
organic materials for medicine
and technology, including for
enterprises of the military-
industrial complex, including
development of materials,
methods and technologies for
production thereof.